GBM, Glioblastoma, Newly Diagnosed Glioblastoma, Recurrent Glioblastoma
Conditions
Keywords
MN-166, GBM, glioblastoma, recurrent GBM, temozolomide, newly diagnosed glioblastoma
Brief summary
Part 1 is an open-label, single-arm, dose escalation study of MN-166 (ibudilast) and temozolomide (TMZ) combination treatment. Evaluate safety and tolerability of ibudilast (MN-166) and TMZ combination treatment for 1 cycle (28 days); determine dosage in dose-finding study. Part 2 will evaluate efficacy of fixed-dose MN-166 (ibudilast) and TMZ combination treatment for 6 cycles (\ 6 months) until disease progression, unacceptable tolerability and/or toxicity or loss of life.
Detailed description
This is a single-center open-label, dose-escalation study to evaluate the safety, tolerability and efficacy of MN-166 (ibudilast) and Temozolomide combination treatment in patients with newly diagnosed or recurrent glioblastoma. To be eligible, subjects are histologically confirmed glioblastoma or gliosarcoma, or astrocytomas with molecular features of glioblastoma, WHO Grade 4. Recurrent glioblastoma patients must have a Karnofsky Performance Status (KPS) ≥70 or Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Patients having newly diagnosed glioblastoma, gliosarcoma, or astrocytomas with molecular features of glioblastoma must have a KPS ≥60 and ECOG score 0-1. This is divided into a dose-escalation phase (Part 1) followed by a fixed-dose phase (Part 2). Part 1 will evaluate the safety and tolerability of MN-166 when given in combination with temozolomide, and determine the dose of MN-166 to be used in Part 2 of the study. Up to 18 adult subjects are planned to be enrolled in Part 1. Part 2 will evaluate the efficacy of MN-166 and temozolomide combination treatment as measured by the proportion of subjects who are progression-free at 6 months. Other outcome measures include the evaluation of overall survival, response rate, and median six-month progression-free survival up to 2 years and up to 50 subjects are planned to be enrolled in Part 2.
Interventions
DRUGMN-166
MN-166 is an anti-inflammatory/neuroprotective agent. MN-166 distributes well to the CNS (Sanftner et al. 2009) and it is a selective inhibitor of certain cyclic nucleotide phosphodiesterases (PDE) and the pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF). At clinically-relevant plasma or CNS concentrations, MN-166 selectively inhibits macrophage migration inhibitory factor (MIF) (Cho et al 2010) and, secondarily, PDE3, 4 and 10 (Gibson et al 2006).
DRUGTemozolomide
Temozolomide is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; and a first-line treatment for glioblastoma multiforme.
Sponsors
MediciNova
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Phase 1b/2a Single-center, Open-label, Dose-escalation study followed by a fixed-dose study to evaluate the safety, tolerability, and preliminary efficacy of MN-166 plus temozolomide in patients with newly diagnosed or recurrent glioblastoma.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Major Inclusion Criteria for Recurrent GBM Patients: 1. Age 18 or older; 2. Histologically confirmed GBM (glioblastoma), WHO Grade 4; 3. Patients must have a Karnofsky Performance Status (KPS) ≥70 or Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (see Appendix 7); 4. Previously received standard front-line GBM treatment including maximal surgical resection followed by external beam radiation therapy and TMZ therapy. Prior use of NovoTTF (Optune) and Gliadel wafers is allowed; 5. Patients must be in first relapse; 1. Relapse is defined as progression following initial therapy (i.e., radiation and/or chemotherapy). The intent therefore is that patients had no more than 1 prior therapy (i.e., initial treatment). If the patient had a surgical resection for relapsed disease and no anti-cancer therapy was instituted for up to 12 weeks, and the patient undergoes another surgical resection, this is considered to constitute one (1) relapse; 2. Documented recurrence or progression by brain MRI imaging ≤14 days before study registration; 3. Measurable disease by RANO criteria (≥ 10 mm x 10 mm). Major Inclusion criteria for newly diagnosed patients: 1. Ages 18 or older; 2. Newly diagnosed glioblastoma or gliosarcoma (WHO Grade 4) confirmed by histology or astrocytomas with molecular features of gliobastoma; 3. Starting maintenance therapy with temozolomide (150 mg/m\^2 on Days 1-5 every 28 days) within 4 weeks prior to screening phase; 4. If patient is receiving corticosteroid, dose must be stable or decreasing for at least 5 days prior to the scan. If steroids are added or the steroid dose is increased between the date of the pretreatment MRI and the start of study, a new baseline MRI or CT scan is required; 5. Karnofsky Performance Status ≥60 at time of screening; 6. ECOG score of 0 or 1 at time of screening; 7. Life expectancy of at least 3 months.
Exclusion criteria
(applied to all patients): 1. History of Grade 2 (CTCAE v4.0) or greater intracranial or intratumoral hemorrhage confirmed by either MRI or CT scan; 2. Current use of anticoagulant treatment with coumadin (low-molecular-weight heparin and factor Xa inhibitors are permitted); 3. Any systemic illness or unstable medical condition that might pose additional risk, including: cardiac, unstable metabolic or endocrine disturbances, renal or liver disease; 4. Patients with a history of a different malignancy except the following circumstances: 1. They have been disease-free for at least 2 years prior to starting study drug and are deemed by the investigator to be at low risk for recurrence of that malignancy. Patients with the following cancers are eligible if diagnosed and treated within the past 2 years: i. Cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin; 7\) Patients who have not recovered to ≤ Grade 1 toxicity by NCI CTCAE v4.0 from the toxic effects of previous therapy with exception of lymphopenia, alopecia and fatigue; 9) For use of other investigational drug or other anti-tumor treatment, the following time periods must have elapsed from the projected start of scheduled study treatment: 1. 4 weeks or 5 half-lives (whichever is shorter) from any investigational agent; 2. 4 weeks from cytotoxic therapy (except 23 days for TMZ; 6 weeks from nitrosoureas); 3. 6 weeks from antibodies treatment (i.e., anti-VEGF antibody); 4. 4 weeks or 5 half-lives (whichever is shorter) from other anti-tumor therapies; 5. 2 days from NOVO-TTF (Optune®).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate safety and tolerability of ibudilast and temozolomide combination treatment | 1-6 months | Determine the proportion of patients with * Treatment-emergent adverse events (TEAEs) as measured by the CTCAE v4.0 and * Treatment discontinuations due to TEAEs and Dose-Limiting Toxicities (DLTs). |
| Evaluate efficacy of ibudilast and TMZ combination treatment | 1-6 months | Proportion of patients who are progression free at 6 months (PFS6) using the RANO criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUC | 1-6 months | Area under the concentration versus time curve from the start of dose administration to the last quantifiable point within the dosing interval. |
| Terminal rate constant | 1-6 months | Calculated from the terminal slope of the log-linear regression of concentration with time. |
| Terminal half-life | 1-6 months | Time required for the plasma concentration of a drug to decrease 50% in the final stage of its elimination |
| Evaluate Tmax | 1-6 months | Time from start of dosing at which the maximum concentration is observed) |
| Evaluate the safety of fixed-dose ibudilast in combination with TMZ | 1-6 months | Reporting of treatment-emergent adverse events * Treatment-emergent adverse events (TEAEs) as measured by the CTCAE v4.0 and * Treatment discontinuations due to TEAEs and Dose-Limiting Toxicities (DLTs). |
| Evaluate overall survival, response rate, and median 6-month progression-free survival (PFS6) | 1-6 months | Overall survival will be measured for each subject with time origin at the date of Study Day 1 until recorded date or death or last follow-up visit. |
| Maximum tolerated dose determination | 1-6 months | Determine maximum tolerable dose of ibudilast taken in combination with TMZ |
| Cmax | 1-6 months | Maximum observed concentration) |
Countries
United States
Outcome results
None listed